Real‐world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma
| العنوان: | Real‐world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma |
|---|---|
| المؤلفون: | Muhammet Ozer, Shu Wang, Andy Surinach, Kenneth H. Yu, Paul Cockrum, Bong Chul Chu |
| المصدر: | Cancer Medicine Cancer Medicine, Vol 10, Iss 24, Pp 8934-8943 (2021) |
| بيانات النشر: | John Wiley and Sons Inc., 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Oncology, Male, Cancer Research, medicine.medical_specialty, FOLFIRINOX, Population, Serum albumin, pancreatic ductal adenocarcinoma, Adenocarcinoma, Internal medicine, White blood cell, Ascites, antineoplastic agents, Medicine, Humans, Radiology, Nuclear Medicine and imaging, Stage (cooking), Neoplasm Metastasis, education, RC254-282, Research Articles, Aged, Retrospective Studies, Aged, 80 and over, education.field_of_study, biology, medicine.diagnostic_test, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Clinical Cancer Research, prognostic factors, real‐world evidence, Middle Aged, Prognosis, Survival Analysis, Gemcitabine, medicine.anatomical_structure, electronic health records, biology.protein, Female, medicine.symptom, business, Liver function tests, treatment options, medicine.drug, Research Article, Carcinoma, Pancreatic Ductal |
| الوصف: | Background Many real‐world studies of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) are restricted to single centers, limiting the generalizability of their insights. This study aimed to identify important population‐based predictors for survival in patients diagnosed with mPDAC in a broader setting. Methods Data between 1 January 2017 and 31 December 2019 were extracted from the Flatiron Health EHR database. Treatment‐specific predictive models were generated for patients treated with first‐line gemcitabine+nabpaclitaxel (GNP), FOLFIRINOX, gemcitabine monotherapy (gem‐mono), and second‐line liposomal irinotecan‐based regimens. The holdout method was used for cross‐validation. Age at diagnosis, sex, BMI, smoking status, and ECOG performance score were included in all models with additional demographic, clinical characteristics, and hematological function assessed for inclusion. Results Of the 3625 patients, 43% received GNP, 26% received FOLFIRINOX, 7% received gem‐mono, and 23% received other regimens; 40% (n = 1448) advanced to the second line. Among all first‐line patients, the following were included in the final model: prior surgery, white blood cell (WBC) counts, serum albumin (SA), liver function tests (LFTs), serum bilirubin, serum carbohydrate antigen 19–9, and ascites. Models for patients receiving specific therapies differed from the overall model, GNP (ascites removed), FOLFIRINOX (stage at initial diagnosis added), and gem‐mono (LFTs omitted). Alkaline phosphatase (ALP), SA, and WBC counts were important predictors of survival among patients treated with second‐line liposomal irinotecan. Across all regimens, the strongest predictors of survival were ECOG score, SA, and ALP. Conclusions In this real‐world study of patients with mPDAC, important population prognostic factors of survival were identified in a large cohort of patients receiving systemic treatment. This retrospective observational analysis of US patient‐level electronic health record data identified a sample of 3625 patients who initiated first‐line systemic therapy for metastatic pancreatic ductal adenocarcinoma from 2017 to 2019. Important population prognostic factors of survival were identified that applied across all regimens including performance status, serum albumin, and alkaline phosphatase levels. Additional patient characteristics were identified as prognostic factors of survival in the context of specific therapies. |
| اللغة: | English |
| تدمد: | 2045-7634 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27a5970d4ddecc75ffb4c52bb442596cTest http://europepmc.org/articles/PMC8683530Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....27a5970d4ddecc75ffb4c52bb442596c |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20457634 |
|---|